DXM (Dextromethorphan)

Dextromethorphan is an over-the-counter cough suppressant found in many cold and flu medications. At therapeutic doses (15-30mg), it acts as an antitussive. At higher doses (100mg+), it produces dissociative and hallucinogenic effects organized into four plateaus of increasing intensity. CRITICAL WARNING: Many OTC products contain acetaminophen, guaifenesin, antihistamines, or other adulterants that are dangerous in high doses. Only use DXM-only products (gel caps, syrups without additives). CYP2D6 poor metabolizers experience extreme risk and rapid overdose.

How It Works

DXM is a non-competitive NMDA receptor antagonist that also shows sigma-1 agonism at high doses. It blocks N-methyl-D-aspartate (NMDA) glutamate receptors, producing dissociation and altered sensory perception similar to ketamine but with additional serotonergic activity. At therapeutic doses, it suppresses the cough reflex via medullary cough center depression.

Legal Status

Over-the-counter (OTC) in most countries. Some jurisdictions restrict sales to minors or ban for non-medical use. Schedule II in some US states when intended for abuse.

Dosage Guide (Oral (DXM-only gel capsules))

Note: DXM plateau system: First plateau (100-300mg) = euphoria/mild dissociation. Second plateau (300-600mg) = significant dissociation/mild hallucinations. Third plateau (600-1000mg) = intense dissociation/strong hallucinations. Fourth plateau (1000mg+) = extreme dissociation/complete loss of body sense. Doses above 1500mg carry severe overdose risk. Tolerance develops rapidly (days). Body weight matters significantly — calculate as mg/kg. CYP2D6 poor metabolizers should use extreme caution; effects can be 2-4x stronger and longer.

Organ System Impacts

cardiovascular — Moderate

Increases heart rate and blood pressure in dose-dependent manner. Risk of arrhythmias, palpitations, and tachycardia. Dissociative effects mask dangerous cardiovascular symptoms. Severe risk if combined with stimulants (cocaine, amphetamine, phenylephrine).

neurological — High

Primary target organ. NMDA antagonism produces dissociation, altered cognition, and motor impairment. Chronic use linked to cognitive decline, memory problems, and potential neurotoxicity. Seizure risk at high doses. Serotonin syndrome possible if combined with SSRIs/MAOIs.

ocular — Low

Dilated pupils (mydriasis). Horizontal nystagmus characteristic at higher doses. Blurred vision and decreased accommodation. Photosensitivity. Generally reversible.

dermatological — Low

Flushing and skin irritation possible. Hypersensitivity reactions rare but documented. Sweating or dry skin. These effects are generally mild and transient.

respiratory — Moderate

Dose-dependent respiratory depression, particularly at high doses and with chronic use. Risk of hypoventilation and hypoxia. More severe if combined with CNS depressants (alcohol, opioids, benzodiazepines). Monitor for shallow breathing.

hepatic — High

DXM undergoes hepatic metabolism via CYP2D6 and CYP3A4. Liver toxicity primarily from contaminants (acetaminophen in some products). DXM itself has low hepatotoxicity but impaired liver function increases risk. Poor metabolizers at extreme risk of accumulation.

hematological — Low

No direct hematological effects documented. Some case reports of thrombocytopenia with chronic heavy use. Generally minimal impact on blood cells.

renal — Moderate

Acute kidney injury reported with high-dose use, particularly in context of rhabdomyolysis or hyperthermia. Chronic use may cause kidney damage. Dehydration during use increases renal stress. Monitor hydration status.

gastrointestinal — Moderate

Nausea and vomiting very common, especially at first and higher plateaus. Constipation from anticholinergic effects. Gastric irritation from acidic syrups. Abdominal cramping possible. Many users report nausea as limiting factor.

musculoskeletal — Moderate

Rhabdomyolysis reported in cases of high doses combined with hyperthermia or intense exertion. Muscle pain and weakness possible. Myoglobinuria can lead to acute renal failure. Risk increased with physical activity during use.

Effects

Desired Effects

• Dissociation
• Euphoria
• Mild hallucinations
• Altered time perception
• Dream-like state
• Visual distortions
• Emotional blunting
• Floating sensation

Negative Effects

• Severe nausea and vomiting
• Dizziness and vertigo
• Impaired coordination
• Loss of balance
• Confusion and disorientation
• Paranoia
• Anxiety
• Poor decision-making
• Memory blackouts
• Respiratory depression (high doses)

Rare but Serious

• Serotonin syndrome
• Seizures
• Psychosis
• Hyperthermia (dangerous if combined with stimulants)
• Acute liver failure (if acetaminophen contamination)
• Severe hypertension
• Cardiac arrhythmias
• Rhabdomyolysis
• Renal acute tubular necrosis

Drug Interactions

Detection Times

DXM can cause false positives for PCP on some immunoassays. Confirmatory testing can distinguish.

Urine

May trigger false positive on PCP immunoassay. Specific testing available. Detection window: up to 3 days.

Blood

Blood testing for DXM and dextrorphan metabolite. Detection window: up to 2 days.

Harm Reduction Tips

• Do not combine with alcohol, opioids, benzodiazepines, or other CNS depressants — severe overdose and respiratory depression risk.

• Avoid SSRIs/MAOIs entirely — serotonin syndrome risk is fatal and reliable.

• Start with lower doses to assess individual sensitivity and metabolism. First-time users prone to severe nausea.

• Test products with reagent tests if available (though reagent testing for purity is limited for DXM).

• Stay hydrated but avoid over-hydration (hyponatremia risk documented with high-dose, extended-duration use).

• Monitor body temperature, especially with physical activity — hyperthermia and rhabdomyolysis risk at high doses.

• Avoid third-plateau and higher doses until familiar with dissociative effects at lower doses.

• Use DXM-only products (gel caps, powders) to avoid dangerous adulterants like acetaminophen, guaifenesin, and antihistamines that are toxic at high doses.

• Check CYP2D6 metabolizer status if possible (genetic testing) — poor metabolizers experience 2-4x stronger effects and delayed metabolism (up to 24+ hours).

• Calculate dosing carefully based on body weight. Effects scale with mg/kg ratio. Use online calculators (erowid.org plateau calculator).

• Ensure you are in safe environment before using, especially at higher plateaus where dissociation is extreme. Do not drive, operate machinery, or use at heights.

• Use with trusted people present. Dissociation can cause dangerous behavior — full supervision recommended for third and fourth plateau doses.

• Avoid any stimulant co-use (caffeine included at high doses) due to cardiovascular risk and hyperthermia potential.

• Allow extended tolerance breaks (weeks-months) between uses. Tolerance develops rapidly; increased redosing increases addiction and toxicity risk.

• Plan for 24+ hour recovery time; dissociation, cognitive impairment, and poor judgment persist long after acute effects.

Withdrawal Symptoms

Severity: Low

Onset: 1-2 days. Acute phase: 3-7 days. Full resolution: 1-3 weeks.

Physical

• Fatigue
• Nausea
• Insomnia
• Sweating

Psychological

• Cravings
• Anxiety
• Dysphoria
• Cognitive fog
• Dissociative symptoms may persist temporarily

Emergency Information

Call 911 If:

• Respiratory depression (breathing fewer than 8 times per minute)
• Loss of consciousness lasting more than a few minutes
• Seizures
• Severe hyperthermia (>103F / 39.4C)
• Chest pain or difficulty breathing
• Signs of psychosis or violent behavior lasting >30 minutes
• Severe muscle rigidity or loss of muscle control
• Signs of serotonin syndrome (fever, rigidity, altered mental status, hyperreflexia)
• Signs of rhabdomyolysis (severe muscle pain, dark urine, weakness)
• Kidney injury signs (decreased urination, brown urine)
• Any overdose concern or ingestion of unknown amount

Warning Signs

• Severe respiratory depression (slow, shallow breathing, blue lips)
• Loss of consciousness or unresponsiveness
• Seizures or convulsions
• Severe hyperthermia (body temperature >103F/39.4C)
• Extreme agitation, violent behavior, or psychosis
• Severe chest pain or pressure (signs of cardiac event)
• Severe hypertension with headache and confusion (hypertensive crisis)
• Rigid muscles and fever (serotonin syndrome signs)
• Inability to move limbs or complete paralysis
• Bleeding or signs of internal injury

What To Do

1. Move person to safe location away from hazards.
2. Check airway, breathing, circulation. Place in recovery position if unconscious.
3. Cool person if hyperthermic (ice packs, cool water, fanning) — hyperthermia can cause organ failure.
4. Do not try to sedate or calm violent person with additional drugs.
5. Keep person's identity information and substance details available for paramedics.
6. Monitor vital signs until help arrives (breathing, heart rate, temperature).
7. Have naloxone (Narcan) available if opioid co-use suspected, though DXM overdose does not directly respond to naloxone.
8. Document what substance was used, estimated dose, route, and time of ingestion.
9. Do not leave person alone.